Business
Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results
INCHEON, Korea, January 26, 2026--Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced financial results for the fourth quarter and fiscal year 2025.
About this update from Samsung Epis Holdings Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":339,"url":"https://media.zenfs.com/en/business-wire.com/dd9727cd67101460d40562e6e5a0c36e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kQ.ZWCK78NPpisB0R_4SBQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY3ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/dd9727cd67101460d40562e6e5a0c36e","width":480,"height":339}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"In its first financial results announcement after the spin-off, Samsung Bioepis recorded FY2025 revenue of KRW 1.672 trillion, highest annual revenue in its 14-year history","length":172,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Excluding milestone revenue, annual sales revenue grew 28% year-over-year (YoY), recording KRW 1.626 trillion, with 101% YoY growth in operating profit to KRW 330.8 billion","length":172,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":344,"olType":false},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"text","content":"INCHEON, Korea, January 26, 2026--(BUSINESS WIRE)--Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced financial results for the fourth quarter and fiscal year 2025.","length":254,"tagName":"p"},{"type":"text","content":""We are very pleased to report strong year-to-date sales growth in our first financial results following the spin-off. Our organic growth has been driven by solid performance across our biosimilars portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. "We are continuing to make meaningful progress in our regulatory and commercial milestones with our existing biosimilars portfolio, while strategically investing in our future pipeline with a disciplined, long-term approach. We aim to drive sustainable growth and create long-term value for our shareholders, so that we can remain committed to improving patient access worldwide."","length":699,"tagName":"p"},{"type":"text","content":"Samsung Bioepis Fourth Quarter & Fiscal Year 2025 Results","length":61,"tagName":"p"},{"type":"text","content":"In the fourth quarter of 2025, S...